Results 51 to 60 of about 5,991,856 (299)

Succinate dehydrogenase (SDH)-deficient renal carcinoma:a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients [PDF]

, 2014
Succinate dehydrogenase (SDH)-deficient renal carcinoma has been accepted as a provisional entity in the 2013 International Society of Urological Pathology Vancouver Classification.
Sedivcová, Monika, Yu, Darryl, Papathomas, Thomas, Niemeijer, Nicolasine D., Przybycin, Christopher, Nicoll, Katherine D, Paik, Julie, Miettinen, Markku, Yong, Jim L., Kedziora, Andrew, Andresen, Per Arne, Hes, Ondrej, Toon, Christopher W., Robinson, Bruce G, Corssmit, Eleonora P M, Michal, Michal, Chou, Angela, Hills, Kirsten, Nicoll, Katherine D., Clarkson, Adele, Clifton-bligh, Roderick J., Yong, Jim L, Maclean, Fiona, Yilmaz, Asli, Vlatkovic, Ljiljana, Niemeijer, Nicolasine D, Hartmann, Arndt, Sibony, Mathilde, Agaimy, Abbas, McKenney, Jesse K, Robinson, Bruce G., Van Leenders, Geert J.l.h., Chow, Chung W., Sioson, Loretta, Mckenney, Jesse K., Corssmit, Eleonora P.m., Tan, Puay Hoon, van Leenders, Geert J L H, Yakirevich, Evgeny, Trpkov, Kiril, Benn, Diana E., Gill, Anthony J., Chow, Chung W, Watson, Nicole, Fleming, Stewart, Magi-Galluzzi, Cristina, Clifton-Bligh, Roderick J   +46 more
core   +1 more source

Effect of DFPP on Ferroptosis in Peripheral Blood CD14+ Monocytes of Hyperlipidemic Patients Involving the ACSL4/LPCAT3/ALOX5 Pathway

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid‐lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non‐drug treatment using double‐filtration plasmapheresis (DFPP) on CD14+
Yun Cheng, Lan Li, Qingmei Yang, Meipeng Wu   +3 more
wiley   +1 more source

Single-cell profiling of the microenvironment in human bone metastatic renal cell carcinoma

Communications Biology
Bone metastasis is of common occurrence in renal cell carcinoma with poor prognosis, but no optimal treatment approach has been established for bone metastatic renal cell carcinoma.
Fen Ma, Shuoer Wang, Lun Xu, Wending Huang, Guohai Shi, Zhengwang Sun, Weiluo Cai, Zhiqiang Wu, Yiming Huang, Juan Meng, Yining Sun, Meng Fang, Mo Cheng, Yingzheng Ji, Tu Hu, Yunkui Zhang, Bingxin Gu, Jiwei Zhang, Shaoli Song, Yidi Sun, Wangjun Yan   +20 more
doaj   +1 more source

A Case of Sarcomatoid Renal Cell Carcinoma With Osseous Metaplasia and Papillary Renal Cell Carcinoma Metastasis

Clinical Pathology, 2019
Sarcomatoid renal cell carcinoma is an uncommon and aggressive renal tumor with rapid disease progression. A median survival time is only 4-9 months after diagnosis. Osteogenic differentiation is a rare feature of the tumor.
Hui Zhang, Nasma K Majeed, Roohollah Sharifi, Grace Guzman   +3 more
doaj   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Characterization of renal artery variation in patients with clear cell renal cell carcinoma and the predictive value of accessory renal artery in pathological grading of renal cell carcinoma: a retrospective and observational study

BMC Cancer, 2023
Objective To explore the characteristics of renal artery variation in patients with renal cell carcinoma and to evaluate the predicting value of accessory renal artery in the pathological grading of renal cell carcinoma.
Dingyang Lv, Huiyu Zhou, Fan Cui, Jie Wen, Weibing Shuang   +4 more
doaj   +1 more source

Xp11.2 Translocation Renal Cell Carcinoma: A Rare Renal Cell Carcinoma

Cureus, 2023
Translocation-associated renal cell carcinoma (TRCC) is a group of under-recognized malignant renal neoplasms owing to the unavailability of ancillary diagnostic tools and considering the fact that these tumors may histomorphologically mimic a heterogeneous group of neoplasms ranging from benign to malignant ones.
Kalita, Pranjal, Dey, Biswajit, Saurabh, Animesh, Chishti, Sheikh F   +3 more
openaire   +2 more sources

Advances in the Treatment of Renal Cell Carcinoma

, 2022
This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this ...

core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source